Latest Platelet Stories

A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists. A team led by Dana Spence of MSU's Department of Chemistry has revealed a way to isolate and test the receptor known as P2X1. By creating a new, simple method to study it after blood is drawn, the team has unlocked a potential new drug target for many diseases that...

Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate of maintenance of platelet inhibition, compared to patients who received placebo, according to a study in the January 18 issue of JAMA. "Thienopyridines [antiplatelet agents] are among the most widely prescribed medications, but their use can be complicated by the...

WAYNE, N.J., Jan. 10, 2012 /PRNewswire/ -- A recent study evaluating the efficacy of the SELPHYL® System was published in Archives of Facial Plastic Surgery by Drs. Anthony P. Sclafani and Steven A. McCormick.[i] The researchers set out to assess the changes in skin after injection of Selphyl, an ultrapure platelet-rich fibrin matrix (PRFM). Utilizing a small amount of the patient's own blood, the system isolates and prepares PRFM for injection back into the patient. The...

WAYNE, N.J., Jan. 6, 2012 /PRNewswire/ -- Cascade Medical Enterprises, LLC (CME), a leading company with proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) technology for use in orthopedic therapeutic applications in soft tissue and bone repair, announced the sale of their technology to Musculoskeletal Transplant Foundation (MTF) and distribution by ConMed Linvatec for the worldwide orthopedic, dental, and wound care markets. CME has had a long...

Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events, according to a study in the December 28 issue of JAMA. Clopidogrel is an antiplatelet...

(Ivanhoe Newswire) – Blood clots are a well-known and serious complication of cancer treatment, and according to a study, 78 percent of the time they occur when a person is out of the hospital. This data is striking because, until now, outpatients had not been systematically studied and previous data gathered on the incidence of blood clots was mostly from hospitalized patients, who tend to be sicker. However, with a shift toward outpatient cancer treatment, future efforts to prevent...

THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from several key Nplate(®) (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm '209 study evaluating the safety and efficacy of Nplate in adults with primary immune thrombocytopenia (ITP)...

PALO ALTO, Calif., Dec. 13, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 1 multicenter dose-ranging trial of the combination of Telintra and Revlimid in patients with International Prognostic System Score (IPSS) Low to Intermediate-1 Risk non-deletion (5q) myelodysplastic syndrome (MDS). The majority of MDS patients are Low to Intermediate-1 Risk non-deletion (5q) and represent an important unmet medical need. Although Revlimid currently...

SAN DIEGO, Dec.10, 2011 /PRNewswire-USNewswire/ -- Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology. Bleeding disorders,...

THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in the safety monitoring program, called the Nplate® NEXUS (Network of EXperts Understanding and Supporting Nplate and Patients) Program, in order to...